Researchers at Southampton University may have the answer. They have recently developed a series of immune system tests which have found a link between a person’s immune cells and their chance of surviving mesothelioma.
What happened in the study?
The researchers looked at tissue samples from 302 patients with advanced malignant mesothelioma. The study investigated immune cell systems as an indication of how well mesothelioma treatment would work.
Initially, the tissue samples were analysed for markers of adaptive immune response. These included t-cells and b-cells.
What did the results show?
The results showed that those with epithelioid mesothelioma had a better outcome when they tested high for T-cell (CD4+) and B-cell (CD20+) and low in T-cell (FOXP3+), macrophages and neutrophils.
Those with non-epithelioid mesothelioma with low counts of T-cell (FOXP3+) also had a good prognosis.
Researcher Serena Chee was pleased with the results and said, “Our data demonstrates for the first time, in predominantly advanced disease, the association of key markers of adaptive and innate immunity with survival and the differential effect of histology (subtype).”
We believe that this is positive research for mesothelioma patients. When patients know how likely they are to survive they can make more informed decisions about their treatment. Furthermore, they may be able to more accurately plan for the future.
How can we help?
If you require assistance in pursuing an asbestos compensation claim then please contact us today. You can call our Freephone number on 0800 038 6767. Alternatively, head over to our ‘contact us’ page and complete the form. One of our Solicitors will be in touch shortly.
Source: Chee, SJ, “Evaluating the effect of immune cells on the outcomes of patients with mesothelioma”, August 17, 2017, British Journal of Cancer.